Tuberculous Meningitis Treatment Guidelines

Core Antimycobacterial Regimen

Administer rifampin and isoniazid for a total of 12 months in all patients with tuberculous meningitis. (British Thoracic Society) 1
Add pyrazinamide for at least the first 2 months because it penetrates cerebrospinal fluid (CSF) well. (British Thoracic Society) 1
Include a fourth drug during the initial 2 months—choose streptomycin, ethambutol (≈15 mg/kg), or ethionamide— to broaden coverage and address possible resistance. (British Thoracic Society) 1
Evidence strength: expert consensus/low‑quality evidence (no randomized trials).

Isoniazid, pyrazinamide, and ethionamide/ethionamide achieve high CSF concentrations, supporting their use in the meningitic phase. (British Thoracic Society) 1
Rifampin attains lower CSF levels than the other agents, but remains a cornerstone of therapy. (British Thoracic Society) 1
Streptomycin and ethambutol reach adequate CSF concentrations only when the meninges are inflamed early in treatment; later they may be sub‑therapeutic. (British Thoracic Society) 1
Intrathecal administration of streptomycin provides no additional benefit and is unnecessary. (British Thoracic Society) 1
Evidence strength: pharmacokinetic data (moderate evidence for penetration; clinical impact uncertain).

Give corticosteroids to patients with stage II or III disease (confused, neurologic signs, or comatose) to reduce inflammatory injury. (British Thoracic Society) 1
Preferred regimen: dexamethasone 6–12 mg/day or prednisone 60–80 mg/day, tapered over 4–8 weeks. (European Respiratory Society) 5
Evidence strength: limited clinical trial data; recommendation based on observational studies (moderate‑low evidence).

Use ethambutol cautiously in stage III (unconscious) patients because ocular toxicity cannot be monitored, although risk is very low at 15 mg/kg. (British Thoracic Society) 1

If pyrazinamide cannot be given, extend the total treatment duration to 18 months to compensate for the loss of early bactericidal activity. (British Thoracic Society) 1

Treat solitary cerebral tuberculoma(s) without meningitis with the same 12‑month regimen used for tuberculous meningitis. (British Thoracic Society) 1

Current recommendations are derived mainly from expert experience at high‑volume centers; randomized controlled trial data are lacking. (British Thoracic Society) 1

Do not apply the standard 6‑month pulmonary TB regimen to meningitis, as it is insufficient for CNS disease. (British Thoracic Society) 6
Do not omit the fourth drug in the intensive phase without assessing drug‑resistance patterns. (British Thoracic Society) 1
Always perform lumbar puncture in patients with miliary TB to detect CNS involvement, given the high rate of hematogenous spread to the meninges. (British Thoracic Society) 7

All facts are presented in English, with patient‑specific details replaced by generic descriptors.